Search PubMed⌕ Search

Biomedical subjects

Dee Anna Glaser

Publications and source records attributed to Dee Anna Glaser.

11 recordsLinked to original sources
PubMed2005

The cosmetic treatment of urticaria pigmentosa with Nd:YAG laser at 532 nanometers.

BACKGROUND: Urticaria pigmentosa is a cutaneous disorder involving infiltration of the skin with mast cells. Histologically the papillary dermis has an increased number of mast cells with an increase in basal layer pigmentation. In addition to possible systemic symptoms, patients with urticaria pigmentosa can suffer emotionally from the cosmetic nature of this skin disease. OBJECTIVE: The purpose was to investigate the use of a diode-pumped Nd:YAG laser at 532 nm for the treatment of the cosmetic comorbidity of urticaria pigmentosa lesions. METHODS: A 19-year-old white male with urticaria pigmentosa had multiple lesions on the dorsum of the hands and forearms. A test site on the right inner arm was treated with a DioLite 532 nanometer laser. Because of satisfaction with the treatment of the test site lesions, multiple lesions on the dorsal hands and forearms were also treated with the DioLite 532 nanometer laser. RESULTS: There was a dramatic clinical reduction in the amount of lesions on the dorsum of the hands and forearms. The test site lesions on the right inner arm had not recurred. CONCLUSION: The diode-pumped Nd:YAG laser at 532 nanometers should be considered part of a dermatologist's armamentarium for the treatment of a patient's cosmetic concerns with lesions of cutaneous mastocytosis.

Journal Article↗
PubMed2005

Body dysmorphic disorder and the liposuction patient.

BACKGROUND: Body dysmorphic disorder (BDD) is an under-recognized disorder that affects a sizeable number of patients who seek cosmetic enhancement, in particular liposuction. Understanding and recognizing BDD can positively impact the care delivered to patients. OBJECTIVE: To familiarize physicians with the presenting signs of BDD and present strategies for caring for BDD patients in a liposuction and/or cosmetic surgery practice. METHODS: Review of currently available literature and diagnostic criteria. RESULTS: BDD affects approximately 1% of patients in the United States, but as many as 7 to 15% of patients seeking cosmetic surgery. Patients with BDD will usually demonstrate an obsession with the area they seek treatment of. In addition, patients with BDD present a unique challenge to the liposuction surgeon. CONCLUSIONS: Physicians who care for patients seeking liposuction or other cosmetic procedures should learn to recognize those who have BDD. Proper recognition and counseling of BDD patients can have a significant positive impact on not only their care but also on the patient-physician relationship. Failure to recognize BDD can, and often does, lead to patient dissatisfaction, as well as difficult future interactions with the BDD patient.

Body Image↗
PubMed2004

Anti-aging products and cosmeceuticals.

Topical therapies can be used as a solo treatment or as an adjunct to the various surgical options to improve upon and maintain the desired anti-aging results. They may also be used as a preventative therapy in younger men and women. Few drugs are currently marketed for the treatment and prevention of skin aging, whereas many cosmeceuticals,the fastest growing segment of the skin-care market, and herbal remedies are touted in the lay press. More than ever, patients are looking for a magical elixir that is easy to use,effective, and inexpensive. The more commonly used products are covered in this article.

Administration, Topical↗
PubMed2004

US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey.

BACKGROUND: The current epidemiologic data on hyperhidrosis are scarce and insufficient to provide precise prevalence or impact estimates. OBJECTIVE: We sought to estimate the prevalence of hyperhidrosis in the US population and assess the impact of sweating on those affected by axillary hyperhidrosis. METHODS: A nationally representative sample of 150,000 households was screened by mailed survey for hyperhidrosis and projected to the US population based on US census data. Ascertainment of hyperhidrosis was based on a question that asked whether participants experienced excessive or abnormal/unusual sweating. RESULTS: The prevalence of hyperhidrosis in the survey sample was 2.9% (6800 individuals). The projected prevalence of hyperhidrosis in the United States is 2.8% (7.8 million individuals), and 50.8% of this population (4.0 million individuals) reported that they have axillary hyperhidrosis (1.4% of the US population). Only 38% had discussed their sweating with a health care professional. Approximately one third of individuals with axillary hyperhidrosis (0.5% of the US population or 1.3 million individuals) reported that their sweating is barely tolerable and frequently interferes, or is intolerable and always interferes, with daily activities. CONCLUSION: Hyperhidrosis affects a much larger proportion of the US population than previously reported. More than half of these individuals have axillary hyperhidrosis, in which sweating can result in occupational, emotional, psychological, social, and physical impairment.

Activities of Daily Living↗
PubMedDate not supplied

Modifications of eyebrow position with botulinum exotoxin A.

OBJECTIVE: To determine if clinically used botulinum exotoxin A (Botox) injections to the forehead and glabellar and crow's-feet regions result in modifications of eyebrow position. DESIGN: Prospective study. SETTING: Academic medical center in St Louis, Mo. SUBJECTS: Twenty-nine adult patients treated with botulinum exotoxin A injections for rhytids. INTERVENTION: The eyebrow position at 13 different sites was measured before injection and 2 weeks after treatment. The areas injected were based on patient preference and physician assessment. Of the 29 patients, 14 received injections into the glabella only and 15 received injections into the glabella and forehead, with or without treatment of the crow's-feet. RESULTS: In 29 patients at rest, we found no significant (P value range,.17 to.97) change in eyebrow position, except for a point depression at the right lateral eyebrow. The 15 patients who received injections into the forehead and glabella, with or without treatment of the crow's-feet, had no significant (P value range,.11 to.84) change in eyebrow position, except for a point of depression at the left medial eyebrow. Both groups exhibited eyebrow depression in the active state (eyebrow maximally elevated). CONCLUSIONS: Botulinum exotoxin A injections into the forehead and glabellar, and crow's-feet regions did not significantly change the resting eyebrow position. However, forehead injections contributed to eyebrow depression in the active state.

Adult↗
PubMedDate not supplied

Acrokeratoelastoidosis.

Acrokeratoelastoidosis of Costa is a rare papular palmoplantar keratosis characterized by small round-oval to rhomboid-shaped, yellowish papules most commonly localized to the palmar surface of the hands and sometimes also found on plantar surfaces of the feet. Both autosomal dominant and sporadic forms of the disease have been reported. Histologically acrokeratoelastoidosis is marked by hyperkeratosis and epidermal hypertrophy. Specific stains for elastic tissue reveal characteristic fragmentation and rarefaction of elastic fibers. We report a sporadic case of acrokeratoelastoidosis in a 13-year-old girl and review the etiology, differential diagnosis, and treatment of this disorder.

Adolescent↗
PubMedDate not supplied

Treatment of axillary hyperhidrosis by chemodenervation of sweat glands using botulinum toxin type A.

Primary axillary hyperhidrosis is a medical condition characterized by excessive underarm sweating that is thought to result from localized hyperstimulation of sweat glands by cholinergic sympathetic nerve fibers. It can be associated with significant professional, physical, and emotional impairment as well as considerable difficulties in social situations and in personal relationships. Available therapies have been limited by short-lived effectiveness and in some cases significant adverse effects that can put patients at risk for potentially serious complications. Chemodenervation of sweat glands using botulinum toxin type A (BTX-A), which has long-lasting therapeutic efficacy with minimal adverse effects, has emerged as a unique therapy for treating primary axillary hyperhidrosis. This article reviews the chemodenervation procedure, including patient preparation, BTX-A administration, and patient assessment and follow-up.

Axilla↗